Document Detail

Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.
MedLine Citation:
PMID:  22445709     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Cinacalcet effectively reduces elevated levels of parathyroid hormone (PTH) in patients with secondary hyperparathyroidism (SHPT), even those with severe disease for whom parathyroidectomy can be the treatment of choice. The objective of this study was to estimate the cost-effectiveness of cinacalcet treatment in hemodialysis patients with severe SHPT in Japan.
STUDY DESIGN: Cost-effectiveness analysis.
SETTING & POPULATION: Patients with severe SHPT (intact PTH >500 pg/mL) who were receiving hemodialysis in Japan.
MODEL, PERSPECTIVE, & TIMEFRAME: A Markov model was constructed from the health care system perspective in Japan. Patients were followed up over their lifetime. Dialysis costs were not included in the base case.
INTERVENTION: Cinacalcet as an addition to conventional treatment compared to conventional treatment alone. In both arms, patients underwent parathyroidectomy if intact PTH level was >500 pg/mL for 6 months and they were eligible for surgery.
OUTCOMES: Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs).
RESULTS: ICERs for cinacalcet for those who were eligible for surgery and those who were not were $352,631/QALY gained and $21,613/QALY gained, respectively. Sensitivity and scenario analyses showed that results were fairly robust to variations in model parameters and assumptions. In the probabilistic sensitivity analysis, cinacalcet was cost-effective in only 0.9% of simulations for those eligible for surgery, but in more than 99.9% of simulations for those ineligible for surgery, if society would be willing to pay $50,000 per additional QALY.
LIMITATIONS: Data for the long-term effect of cinacalcet on patient-level outcomes are limited. The model predicted rates for clinical events using data for the surrogate biochemical end points.
CONCLUSIONS: The use of cinacalcet to treat severe SHPT is likely to be cost-effective for only those who cannot undergo parathyroid surgery for medical or personal reasons.
Hirotaka Komaba; Kensuke Moriwaki; Shunsuke Goto; Shunsuke Yamada; Masatomo Taniguchi; Takatoshi Kakuta; Isao Kamae; Masafumi Fukagawa
Related Documents :
22759719 - Therapeutic effects of maximal strength training on walking efficiency in patients with...
22497779 - The effect of nesiritide on renal function and other clinical parameters in patients wi...
19212259 - Effect of nitrous oxide use on long-term neurologic and neuropsychological outcome in p...
22619619 - The effect of admission creatinine levels on one-year mortality in acute myocardial inf...
18585509 - Correlates of late and very late thrombosis of drug eluting stents.
17591479 - Time-limited fluoroscopy to reduce radiation exposure during ercp: a prospective random...
7648219 - Relative benefits of different antihypertensive drugs in the prevention of vascular com...
4022079 - Long-term metabolic control with insulin pump therapy. report of experience with 127 pa...
25341739 - The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-03-24
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  60     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-18     Completed Date:  2012-09-28     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  262-71     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cost-Benefit Analysis
Costs and Cost Analysis
Hyperparathyroidism, Secondary / drug therapy*,  economics,  etiology
Kidney Failure, Chronic / complications
Markov Chains
Middle Aged
Monte Carlo Method
Naphthalenes / economics*,  therapeutic use*
Quality-Adjusted Life Years
Renal Dialysis
Reg. No./Substance:
0/Naphthalenes; UAZ6V7728S/cinacalcet
Comment In:
Am J Kidney Dis. 2012 Aug;60(2):179-81   [PMID:  22805518 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  GFR and Cardiovascular Outcomes After Acute Myocardial Infarction: Results From the Korea Acute Myoc...
Next Document:  Photon emission probabilities of (176)Lu.